Hookipa Pharma: Funding, Investors & Team (Sep 2026)
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. Hookipa´s TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers. Hookipa has completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV) and is finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)- related head and neck cancers.
Hookipa Pharma has raised $96.3M across 2 funding rounds on record, the most recent an undisclosed round of $21.3M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Hookipa Pharma Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Hookipa Pharma Funding Rounds
Hookipa Pharma raised $75.0M in a Post-IPO Equity announced in Mar 2022.
1.8 years later, an undisclosed round of $21.3M was announced in Dec 2023.
Hookipa Pharma Founders and Leadership Team
Contact details for the Hookipa Pharma team: 1 of 2 have an email address on file.
Start 14-day free trial →Hookipa Pharma Funding Compared to Other Biotechnology Startups
Hookipa Pharma's latest round of $21.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Hookipa Pharma in Biotechnology and Vienna
Companies Similar to Hookipa Pharma
Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell…
VALANX Biotech creates a unique method of attaching proteins to specific sites for use in treatments,…
aTension.life is a company dedicated to improving the diagnosis and treatment of hypertension using precision…
Millions of people worldwide suffer from brain-related issues that can already be addressed with the latest…
The patented technology developed by Lignovations allows for the creation of lignin particles in the…
Sarcura creates a machine platform for the mass production of customized cell therapies in industry. Our goal…
Arkeon Bio is a biotechnology company that captures CO2 from industry and converts inorganic gases into…
Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
Hookipa Pharma Funding FAQs
What does Hookipa Pharma do?
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. Hookipa´s TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers. Hookipa has completed the active phase of a Phase 1 trial of a Vaxwave®-based vaccine against cytomegalovirus (CMV) and is finalizing clinical development plans for TheraT® in Human Papilloma Virus (HPV)- related head and neck cancers.
How much funding has Hookipa Pharma raised?
Hookipa Pharma has raised $96.3M across 2 rounds on record. The most recent is an undisclosed round of $21.3M announced in Dec 2023.
When did Hookipa Pharma last raise funding?
Hookipa Pharma's most recent funding round on record is an undisclosed round of $21.3M, announced in Dec 2023.
Who founded Hookipa Pharma?
FundedIQ lists Rolf Zinkernagel (Founder) at Hookipa Pharma.
Who is the CEO of Hookipa Pharma?
Jorn Aldag is listed as CEO at Hookipa Pharma.
Where is Hookipa Pharma headquartered?
Hookipa Pharma is based in Vienna, Wien, Austria.
How many employees does Hookipa Pharma have?
Hookipa Pharma is in the 101-250 employee band.
How does Hookipa Pharma's funding compare to other Biotechnology startups?
Hookipa Pharma's latest round of $21.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Hookipa Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Hookipa Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.